First patient completed observation period following PBGENE-DMD treatment with no reported safety concerns - - Independent Data Safety Monitoring Board endorses proceeding with ...
Shares Outstanding: Korsana has approximately 55.1 million shares of the Company’s common stock and common stock equivalents outstanding, including shares of common stock underlying pre-funded ...
WAYNE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results